nodes	percent_of_prediction	percent_of_DWPC	metapath
Tretinoin—CYP4A11—Cisplatin—urinary bladder cancer	0.156	0.37	CbGbCtD
Tretinoin—CYP2B6—Thiotepa—urinary bladder cancer	0.0786	0.186	CbGbCtD
Tretinoin—CYP2A6—Fluorouracil—urinary bladder cancer	0.0392	0.0928	CbGbCtD
Tretinoin—CYP3A4—Thiotepa—urinary bladder cancer	0.0242	0.0571	CbGbCtD
Tretinoin—CYP2B6—Cisplatin—urinary bladder cancer	0.0217	0.0513	CbGbCtD
Tretinoin—CYP2C8—Fluorouracil—urinary bladder cancer	0.0194	0.0458	CbGbCtD
Tretinoin—CYP3A5—Etoposide—urinary bladder cancer	0.0168	0.0397	CbGbCtD
Tretinoin—CYP2C8—Etoposide—urinary bladder cancer	0.0161	0.0382	CbGbCtD
Tretinoin—CYP2B6—Doxorubicin—urinary bladder cancer	0.0145	0.0344	CbGbCtD
Tretinoin—CYP2C9—Fluorouracil—urinary bladder cancer	0.0135	0.0319	CbGbCtD
Tretinoin—CYP2C9—Cisplatin—urinary bladder cancer	0.0115	0.0271	CbGbCtD
Tretinoin—CYP3A4—Etoposide—urinary bladder cancer	0.00655	0.0155	CbGbCtD
Tretinoin—GPRC5A—renal system—urinary bladder cancer	0.00627	0.0489	CbGeAlD
Tretinoin—GPRC5A—female reproductive system—urinary bladder cancer	0.00502	0.0391	CbGeAlD
Tretinoin—RARRES1—prostate gland—urinary bladder cancer	0.00465	0.0363	CbGeAlD
Tretinoin—CYP3A4—Doxorubicin—urinary bladder cancer	0.00447	0.0106	CbGbCtD
Tretinoin—RARRES1—seminal vesicle—urinary bladder cancer	0.00393	0.0307	CbGeAlD
Tretinoin—ALDH1A2—prostate gland—urinary bladder cancer	0.00357	0.0278	CbGeAlD
Tretinoin—CRABP1—prostate gland—urinary bladder cancer	0.00344	0.0268	CbGeAlD
Tretinoin—RARRES1—urethra—urinary bladder cancer	0.00311	0.0243	CbGeAlD
Tretinoin—CRABP2—prostate gland—urinary bladder cancer	0.00311	0.0243	CbGeAlD
Tretinoin—RARB—prostate gland—urinary bladder cancer	0.00278	0.0217	CbGeAlD
Tretinoin—RXRG—prostate gland—urinary bladder cancer	0.00272	0.0212	CbGeAlD
Tretinoin—CRABP2—seminal vesicle—urinary bladder cancer	0.00263	0.0205	CbGeAlD
Tretinoin—ALDH1A1—prostate gland—urinary bladder cancer	0.00259	0.0202	CbGeAlD
Tretinoin—RARRES1—female reproductive system—urinary bladder cancer	0.00254	0.0198	CbGeAlD
Tretinoin—ALDH1A2—renal system—urinary bladder cancer	0.00243	0.019	CbGeAlD
Tretinoin—ALDH1A2—urethra—urinary bladder cancer	0.00239	0.0186	CbGeAlD
Tretinoin—CYP4A11—renal system—urinary bladder cancer	0.00235	0.0183	CbGeAlD
Tretinoin—CRABP1—urethra—urinary bladder cancer	0.0023	0.018	CbGeAlD
Tretinoin—RARRES1—vagina—urinary bladder cancer	0.0023	0.0179	CbGeAlD
Tretinoin—RARG—prostate gland—urinary bladder cancer	0.00227	0.0177	CbGeAlD
Tretinoin—CRABP2—smooth muscle tissue—urinary bladder cancer	0.0022	0.0172	CbGeAlD
Tretinoin—ALDH1A1—seminal vesicle—urinary bladder cancer	0.00219	0.0171	CbGeAlD
Tretinoin—NR0B1—female reproductive system—urinary bladder cancer	0.00218	0.017	CbGeAlD
Tretinoin—RARA—prostate gland—urinary bladder cancer	0.00214	0.0166	CbGeAlD
Tretinoin—RXRA—renal system—urinary bladder cancer	0.00211	0.0165	CbGeAlD
Tretinoin—CYP2C9—urine—urinary bladder cancer	0.00209	0.0163	CbGeAlD
Tretinoin—CRABP2—urethra—urinary bladder cancer	0.00208	0.0162	CbGeAlD
Tretinoin—ALDH1A1—Idarubicin—Valrubicin—urinary bladder cancer	0.00204	0.333	CbGdCrCtD
Tretinoin—ALDH1A2—female reproductive system—urinary bladder cancer	0.00195	0.0152	CbGeAlD
Tretinoin—CRABP1—female reproductive system—urinary bladder cancer	0.00188	0.0146	CbGeAlD
Tretinoin—ALDH1A1—smooth muscle tissue—urinary bladder cancer	0.00184	0.0143	CbGeAlD
Tretinoin—ALDH1A1—renal system—urinary bladder cancer	0.00177	0.0138	CbGeAlD
Tretinoin—ALDH1A2—vagina—urinary bladder cancer	0.00176	0.0137	CbGeAlD
Tretinoin—ALDH1A1—urethra—urinary bladder cancer	0.00174	0.0135	CbGeAlD
Tretinoin—CYP4A11—vagina—urinary bladder cancer	0.0017	0.0132	CbGeAlD
Tretinoin—CRABP1—vagina—urinary bladder cancer	0.0017	0.0132	CbGeAlD
Tretinoin—CRABP2—female reproductive system—urinary bladder cancer	0.0017	0.0132	CbGeAlD
Tretinoin—RXRA—female reproductive system—urinary bladder cancer	0.00169	0.0132	CbGeAlD
Tretinoin—CYP3A4—urine—urinary bladder cancer	0.0016	0.0124	CbGeAlD
Tretinoin—CRABP2—vagina—urinary bladder cancer	0.00154	0.012	CbGeAlD
Tretinoin—RARG—urethra—urinary bladder cancer	0.00152	0.0119	CbGeAlD
Tretinoin—RARB—female reproductive system—urinary bladder cancer	0.00152	0.0118	CbGeAlD
Tretinoin—CYP2A6—prostate gland—urinary bladder cancer	0.00151	0.0117	CbGeAlD
Tretinoin—RARRES1—lymph node—urinary bladder cancer	0.00148	0.0116	CbGeAlD
Tretinoin—RARA—renal system—urinary bladder cancer	0.00146	0.0113	CbGeAlD
Tretinoin—ALDH1A1—female reproductive system—urinary bladder cancer	0.00142	0.011	CbGeAlD
Tretinoin—RARB—vagina—urinary bladder cancer	0.00137	0.0107	CbGeAlD
Tretinoin—ALDH1A1—Podofilox—Etoposide—urinary bladder cancer	0.00136	0.222	CbGdCrCtD
Tretinoin—ALDH1A1—Teniposide—Etoposide—urinary bladder cancer	0.00136	0.222	CbGdCrCtD
Tretinoin—ALDH1A1—vagina—urinary bladder cancer	0.00128	0.00998	CbGeAlD
Tretinoin—CYP2A6—seminal vesicle—urinary bladder cancer	0.00127	0.00994	CbGeAlD
Tretinoin—RXRB—vagina—urinary bladder cancer	0.00126	0.00985	CbGeAlD
Tretinoin—RARG—female reproductive system—urinary bladder cancer	0.00124	0.00966	CbGeAlD
Tretinoin—RARA—female reproductive system—urinary bladder cancer	0.00117	0.00909	CbGeAlD
Tretinoin—ALDH1A2—lymph node—urinary bladder cancer	0.00114	0.00888	CbGeAlD
Tretinoin—CYP2C18—vagina—urinary bladder cancer	0.00113	0.00878	CbGeAlD
Tretinoin—RARG—vagina—urinary bladder cancer	0.00112	0.00874	CbGeAlD
Tretinoin—RARB—lymph node—urinary bladder cancer	0.000889	0.00693	CbGeAlD
Tretinoin—ALDH1A1—lymph node—urinary bladder cancer	0.000828	0.00646	CbGeAlD
Tretinoin—CYP3A5—prostate gland—urinary bladder cancer	0.000763	0.00595	CbGeAlD
Tretinoin—CYP2A6—vagina—urinary bladder cancer	0.000744	0.0058	CbGeAlD
Tretinoin—RARG—lymph node—urinary bladder cancer	0.000725	0.00565	CbGeAlD
Tretinoin—ALDH1A1—Idarubicin—Epirubicin—urinary bladder cancer	0.00071	0.116	CbGdCrCtD
Tretinoin—RARA—lymph node—urinary bladder cancer	0.000682	0.00532	CbGeAlD
Tretinoin—ALDH1A1—Idarubicin—Doxorubicin—urinary bladder cancer	0.000657	0.107	CbGdCrCtD
Tretinoin—CYP2C8—renal system—urinary bladder cancer	0.000577	0.0045	CbGeAlD
Tretinoin—CYP1A1—epithelium—urinary bladder cancer	0.000574	0.00447	CbGeAlD
Tretinoin—CYP1A1—renal system—urinary bladder cancer	0.000532	0.00415	CbGeAlD
Tretinoin—CYP1A1—urethra—urinary bladder cancer	0.000523	0.00408	CbGeAlD
Tretinoin—CYP3A5—renal system—urinary bladder cancer	0.00052	0.00406	CbGeAlD
Tretinoin—CYP2B6—renal system—urinary bladder cancer	0.000517	0.00403	CbGeAlD
Tretinoin—CYP2C8—female reproductive system—urinary bladder cancer	0.000462	0.0036	CbGeAlD
Tretinoin—CYP1A1—female reproductive system—urinary bladder cancer	0.000426	0.00332	CbGeAlD
Tretinoin—CYP2C8—vagina—urinary bladder cancer	0.000418	0.00326	CbGeAlD
Tretinoin—CYP2B6—female reproductive system—urinary bladder cancer	0.000414	0.00323	CbGeAlD
Tretinoin—CYP2C9—female reproductive system—urinary bladder cancer	0.00041	0.0032	CbGeAlD
Tretinoin—CYP3A4—renal system—urinary bladder cancer	0.000391	0.00304	CbGeAlD
Tretinoin—CYP1A1—vagina—urinary bladder cancer	0.000385	0.00301	CbGeAlD
Tretinoin—CYP3A5—vagina—urinary bladder cancer	0.000377	0.00294	CbGeAlD
Tretinoin—CYP2B6—vagina—urinary bladder cancer	0.000375	0.00292	CbGeAlD
Tretinoin—CYP3A4—female reproductive system—urinary bladder cancer	0.000313	0.00244	CbGeAlD
Tretinoin—CYP1A1—lymph node—urinary bladder cancer	0.000249	0.00194	CbGeAlD
Tretinoin—Body temperature increased—Etoposide—urinary bladder cancer	7.96e-05	0.000309	CcSEcCtD
Tretinoin—Abdominal pain—Etoposide—urinary bladder cancer	7.96e-05	0.000309	CcSEcCtD
Tretinoin—Urinary tract infection—Doxorubicin—urinary bladder cancer	7.96e-05	0.000309	CcSEcCtD
Tretinoin—Conjunctivitis—Doxorubicin—urinary bladder cancer	7.96e-05	0.000309	CcSEcCtD
Tretinoin—Haemorrhage—Epirubicin—urinary bladder cancer	7.94e-05	0.000308	CcSEcCtD
Tretinoin—Hepatitis—Epirubicin—urinary bladder cancer	7.94e-05	0.000308	CcSEcCtD
Tretinoin—Eye disorder—Methotrexate—urinary bladder cancer	7.93e-05	0.000308	CcSEcCtD
Tretinoin—Diarrhoea—Fluorouracil—urinary bladder cancer	7.93e-05	0.000308	CcSEcCtD
Tretinoin—Tinnitus—Methotrexate—urinary bladder cancer	7.91e-05	0.000307	CcSEcCtD
Tretinoin—Hypoaesthesia—Epirubicin—urinary bladder cancer	7.9e-05	0.000307	CcSEcCtD
Tretinoin—Asthenia—Cisplatin—urinary bladder cancer	7.88e-05	0.000306	CcSEcCtD
Tretinoin—Pharyngitis—Epirubicin—urinary bladder cancer	7.88e-05	0.000306	CcSEcCtD
Tretinoin—Sweating—Doxorubicin—urinary bladder cancer	7.85e-05	0.000305	CcSEcCtD
Tretinoin—Urinary tract disorder—Epirubicin—urinary bladder cancer	7.84e-05	0.000305	CcSEcCtD
Tretinoin—Oedema peripheral—Epirubicin—urinary bladder cancer	7.82e-05	0.000304	CcSEcCtD
Tretinoin—Haematuria—Doxorubicin—urinary bladder cancer	7.8e-05	0.000303	CcSEcCtD
Tretinoin—Urethral disorder—Epirubicin—urinary bladder cancer	7.78e-05	0.000302	CcSEcCtD
Tretinoin—Epistaxis—Doxorubicin—urinary bladder cancer	7.72e-05	0.0003	CcSEcCtD
Tretinoin—Angiopathy—Methotrexate—urinary bladder cancer	7.7e-05	0.000299	CcSEcCtD
Tretinoin—Sinusitis—Doxorubicin—urinary bladder cancer	7.68e-05	0.000298	CcSEcCtD
Tretinoin—Dizziness—Fluorouracil—urinary bladder cancer	7.66e-05	0.000298	CcSEcCtD
Tretinoin—Visual impairment—Epirubicin—urinary bladder cancer	7.65e-05	0.000297	CcSEcCtD
Tretinoin—Agranulocytosis—Doxorubicin—urinary bladder cancer	7.64e-05	0.000297	CcSEcCtD
Tretinoin—Chills—Methotrexate—urinary bladder cancer	7.61e-05	0.000296	CcSEcCtD
Tretinoin—Diarrhoea—Cisplatin—urinary bladder cancer	7.52e-05	0.000292	CcSEcCtD
Tretinoin—Erythema multiforme—Epirubicin—urinary bladder cancer	7.51e-05	0.000292	CcSEcCtD
Tretinoin—Alopecia—Methotrexate—urinary bladder cancer	7.5e-05	0.000291	CcSEcCtD
Tretinoin—Vomiting—Gemcitabine—urinary bladder cancer	7.49e-05	0.000291	CcSEcCtD
Tretinoin—Mental disorder—Methotrexate—urinary bladder cancer	7.43e-05	0.000289	CcSEcCtD
Tretinoin—Rash—Gemcitabine—urinary bladder cancer	7.43e-05	0.000289	CcSEcCtD
Tretinoin—Dermatitis—Gemcitabine—urinary bladder cancer	7.42e-05	0.000288	CcSEcCtD
Tretinoin—Eye disorder—Epirubicin—urinary bladder cancer	7.42e-05	0.000288	CcSEcCtD
Tretinoin—Hypersensitivity—Etoposide—urinary bladder cancer	7.42e-05	0.000288	CcSEcCtD
Tretinoin—Tinnitus—Epirubicin—urinary bladder cancer	7.4e-05	0.000288	CcSEcCtD
Tretinoin—Malnutrition—Methotrexate—urinary bladder cancer	7.39e-05	0.000287	CcSEcCtD
Tretinoin—Erythema—Methotrexate—urinary bladder cancer	7.39e-05	0.000287	CcSEcCtD
Tretinoin—Haemoglobin—Doxorubicin—urinary bladder cancer	7.39e-05	0.000287	CcSEcCtD
Tretinoin—Headache—Gemcitabine—urinary bladder cancer	7.38e-05	0.000287	CcSEcCtD
Tretinoin—Flushing—Epirubicin—urinary bladder cancer	7.37e-05	0.000286	CcSEcCtD
Tretinoin—Vomiting—Fluorouracil—urinary bladder cancer	7.37e-05	0.000286	CcSEcCtD
Tretinoin—Haemorrhage—Doxorubicin—urinary bladder cancer	7.35e-05	0.000285	CcSEcCtD
Tretinoin—Hepatitis—Doxorubicin—urinary bladder cancer	7.35e-05	0.000285	CcSEcCtD
Tretinoin—Hypoaesthesia—Doxorubicin—urinary bladder cancer	7.31e-05	0.000284	CcSEcCtD
Tretinoin—Rash—Fluorouracil—urinary bladder cancer	7.31e-05	0.000284	CcSEcCtD
Tretinoin—Dermatitis—Fluorouracil—urinary bladder cancer	7.3e-05	0.000284	CcSEcCtD
Tretinoin—Pharyngitis—Doxorubicin—urinary bladder cancer	7.29e-05	0.000283	CcSEcCtD
Tretinoin—Headache—Fluorouracil—urinary bladder cancer	7.26e-05	0.000282	CcSEcCtD
Tretinoin—Urinary tract disorder—Doxorubicin—urinary bladder cancer	7.26e-05	0.000282	CcSEcCtD
Tretinoin—Oedema peripheral—Doxorubicin—urinary bladder cancer	7.24e-05	0.000281	CcSEcCtD
Tretinoin—Asthenia—Etoposide—urinary bladder cancer	7.22e-05	0.000281	CcSEcCtD
Tretinoin—Angiopathy—Epirubicin—urinary bladder cancer	7.2e-05	0.00028	CcSEcCtD
Tretinoin—Urethral disorder—Doxorubicin—urinary bladder cancer	7.2e-05	0.00028	CcSEcCtD
Tretinoin—Back pain—Methotrexate—urinary bladder cancer	7.15e-05	0.000278	CcSEcCtD
Tretinoin—Chills—Epirubicin—urinary bladder cancer	7.13e-05	0.000277	CcSEcCtD
Tretinoin—Pruritus—Etoposide—urinary bladder cancer	7.12e-05	0.000277	CcSEcCtD
Tretinoin—Arrhythmia—Epirubicin—urinary bladder cancer	7.09e-05	0.000276	CcSEcCtD
Tretinoin—Visual impairment—Doxorubicin—urinary bladder cancer	7.08e-05	0.000275	CcSEcCtD
Tretinoin—Alopecia—Epirubicin—urinary bladder cancer	7.02e-05	0.000273	CcSEcCtD
Tretinoin—Nausea—Gemcitabine—urinary bladder cancer	7e-05	0.000272	CcSEcCtD
Tretinoin—Vomiting—Cisplatin—urinary bladder cancer	6.99e-05	0.000271	CcSEcCtD
Tretinoin—Vision blurred—Methotrexate—urinary bladder cancer	6.96e-05	0.00027	CcSEcCtD
Tretinoin—Mental disorder—Epirubicin—urinary bladder cancer	6.96e-05	0.00027	CcSEcCtD
Tretinoin—Erythema multiforme—Doxorubicin—urinary bladder cancer	6.95e-05	0.00027	CcSEcCtD
Tretinoin—Rash—Cisplatin—urinary bladder cancer	6.93e-05	0.000269	CcSEcCtD
Tretinoin—Dermatitis—Cisplatin—urinary bladder cancer	6.92e-05	0.000269	CcSEcCtD
Tretinoin—Malnutrition—Epirubicin—urinary bladder cancer	6.91e-05	0.000269	CcSEcCtD
Tretinoin—Erythema—Epirubicin—urinary bladder cancer	6.91e-05	0.000269	CcSEcCtD
Tretinoin—Diarrhoea—Etoposide—urinary bladder cancer	6.89e-05	0.000268	CcSEcCtD
Tretinoin—Nausea—Fluorouracil—urinary bladder cancer	6.88e-05	0.000267	CcSEcCtD
Tretinoin—Eye disorder—Doxorubicin—urinary bladder cancer	6.87e-05	0.000267	CcSEcCtD
Tretinoin—Ill-defined disorder—Methotrexate—urinary bladder cancer	6.85e-05	0.000266	CcSEcCtD
Tretinoin—Tinnitus—Doxorubicin—urinary bladder cancer	6.85e-05	0.000266	CcSEcCtD
Tretinoin—Anaemia—Methotrexate—urinary bladder cancer	6.83e-05	0.000265	CcSEcCtD
Tretinoin—Flushing—Doxorubicin—urinary bladder cancer	6.82e-05	0.000265	CcSEcCtD
Tretinoin—Flatulence—Epirubicin—urinary bladder cancer	6.81e-05	0.000265	CcSEcCtD
Tretinoin—Tension—Epirubicin—urinary bladder cancer	6.78e-05	0.000264	CcSEcCtD
Tretinoin—Nervousness—Epirubicin—urinary bladder cancer	6.71e-05	0.000261	CcSEcCtD
Tretinoin—Back pain—Epirubicin—urinary bladder cancer	6.69e-05	0.00026	CcSEcCtD
Tretinoin—Angiopathy—Doxorubicin—urinary bladder cancer	6.67e-05	0.000259	CcSEcCtD
Tretinoin—Malaise—Methotrexate—urinary bladder cancer	6.66e-05	0.000259	CcSEcCtD
Tretinoin—Dizziness—Etoposide—urinary bladder cancer	6.66e-05	0.000259	CcSEcCtD
Tretinoin—Chills—Doxorubicin—urinary bladder cancer	6.59e-05	0.000256	CcSEcCtD
Tretinoin—Arrhythmia—Doxorubicin—urinary bladder cancer	6.56e-05	0.000255	CcSEcCtD
Tretinoin—Nausea—Cisplatin—urinary bladder cancer	6.53e-05	0.000253	CcSEcCtD
Tretinoin—Vision blurred—Epirubicin—urinary bladder cancer	6.51e-05	0.000253	CcSEcCtD
Tretinoin—Alopecia—Doxorubicin—urinary bladder cancer	6.49e-05	0.000252	CcSEcCtD
Tretinoin—Cough—Methotrexate—urinary bladder cancer	6.45e-05	0.00025	CcSEcCtD
Tretinoin—Mental disorder—Doxorubicin—urinary bladder cancer	6.44e-05	0.00025	CcSEcCtD
Tretinoin—Ill-defined disorder—Epirubicin—urinary bladder cancer	6.41e-05	0.000249	CcSEcCtD
Tretinoin—Convulsion—Methotrexate—urinary bladder cancer	6.4e-05	0.000249	CcSEcCtD
Tretinoin—Vomiting—Etoposide—urinary bladder cancer	6.4e-05	0.000249	CcSEcCtD
Tretinoin—Malnutrition—Doxorubicin—urinary bladder cancer	6.4e-05	0.000248	CcSEcCtD
Tretinoin—Erythema—Doxorubicin—urinary bladder cancer	6.4e-05	0.000248	CcSEcCtD
Tretinoin—Anaemia—Epirubicin—urinary bladder cancer	6.39e-05	0.000248	CcSEcCtD
Tretinoin—Agitation—Epirubicin—urinary bladder cancer	6.35e-05	0.000247	CcSEcCtD
Tretinoin—Rash—Etoposide—urinary bladder cancer	6.35e-05	0.000247	CcSEcCtD
Tretinoin—Dermatitis—Etoposide—urinary bladder cancer	6.34e-05	0.000246	CcSEcCtD
Tretinoin—Headache—Etoposide—urinary bladder cancer	6.31e-05	0.000245	CcSEcCtD
Tretinoin—Flatulence—Doxorubicin—urinary bladder cancer	6.3e-05	0.000245	CcSEcCtD
Tretinoin—Myalgia—Methotrexate—urinary bladder cancer	6.29e-05	0.000244	CcSEcCtD
Tretinoin—Chest pain—Methotrexate—urinary bladder cancer	6.29e-05	0.000244	CcSEcCtD
Tretinoin—Arthralgia—Methotrexate—urinary bladder cancer	6.29e-05	0.000244	CcSEcCtD
Tretinoin—Tension—Doxorubicin—urinary bladder cancer	6.28e-05	0.000244	CcSEcCtD
Tretinoin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	6.25e-05	0.000243	CcSEcCtD
Tretinoin—Malaise—Epirubicin—urinary bladder cancer	6.23e-05	0.000242	CcSEcCtD
Tretinoin—Discomfort—Methotrexate—urinary bladder cancer	6.21e-05	0.000241	CcSEcCtD
Tretinoin—Nervousness—Doxorubicin—urinary bladder cancer	6.21e-05	0.000241	CcSEcCtD
Tretinoin—Syncope—Epirubicin—urinary bladder cancer	6.2e-05	0.000241	CcSEcCtD
Tretinoin—Back pain—Doxorubicin—urinary bladder cancer	6.19e-05	0.00024	CcSEcCtD
Tretinoin—Palpitations—Epirubicin—urinary bladder cancer	6.11e-05	0.000237	CcSEcCtD
Tretinoin—Confusional state—Methotrexate—urinary bladder cancer	6.08e-05	0.000236	CcSEcCtD
Tretinoin—Loss of consciousness—Epirubicin—urinary bladder cancer	6.08e-05	0.000236	CcSEcCtD
Tretinoin—Cough—Epirubicin—urinary bladder cancer	6.03e-05	0.000234	CcSEcCtD
Tretinoin—Anaphylactic shock—Methotrexate—urinary bladder cancer	6.03e-05	0.000234	CcSEcCtD
Tretinoin—Vision blurred—Doxorubicin—urinary bladder cancer	6.03e-05	0.000234	CcSEcCtD
Tretinoin—Convulsion—Epirubicin—urinary bladder cancer	5.99e-05	0.000233	CcSEcCtD
Tretinoin—Infection—Methotrexate—urinary bladder cancer	5.99e-05	0.000233	CcSEcCtD
Tretinoin—Nausea—Etoposide—urinary bladder cancer	5.98e-05	0.000232	CcSEcCtD
Tretinoin—Hypertension—Epirubicin—urinary bladder cancer	5.97e-05	0.000232	CcSEcCtD
Tretinoin—Ill-defined disorder—Doxorubicin—urinary bladder cancer	5.93e-05	0.000231	CcSEcCtD
Tretinoin—Nervous system disorder—Methotrexate—urinary bladder cancer	5.91e-05	0.00023	CcSEcCtD
Tretinoin—Anaemia—Doxorubicin—urinary bladder cancer	5.91e-05	0.00023	CcSEcCtD
Tretinoin—Thrombocytopenia—Methotrexate—urinary bladder cancer	5.9e-05	0.000229	CcSEcCtD
Tretinoin—Arthralgia—Epirubicin—urinary bladder cancer	5.89e-05	0.000229	CcSEcCtD
Tretinoin—Chest pain—Epirubicin—urinary bladder cancer	5.89e-05	0.000229	CcSEcCtD
Tretinoin—Myalgia—Epirubicin—urinary bladder cancer	5.89e-05	0.000229	CcSEcCtD
Tretinoin—Agitation—Doxorubicin—urinary bladder cancer	5.88e-05	0.000228	CcSEcCtD
Tretinoin—Anxiety—Epirubicin—urinary bladder cancer	5.86e-05	0.000228	CcSEcCtD
Tretinoin—Skin disorder—Methotrexate—urinary bladder cancer	5.86e-05	0.000227	CcSEcCtD
Tretinoin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	5.84e-05	0.000227	CcSEcCtD
Tretinoin—Hyperhidrosis—Methotrexate—urinary bladder cancer	5.83e-05	0.000226	CcSEcCtD
Tretinoin—Discomfort—Epirubicin—urinary bladder cancer	5.81e-05	0.000226	CcSEcCtD
Tretinoin—Malaise—Doxorubicin—urinary bladder cancer	5.77e-05	0.000224	CcSEcCtD
Tretinoin—Dry mouth—Epirubicin—urinary bladder cancer	5.76e-05	0.000224	CcSEcCtD
Tretinoin—Anorexia—Methotrexate—urinary bladder cancer	5.75e-05	0.000223	CcSEcCtD
Tretinoin—Syncope—Doxorubicin—urinary bladder cancer	5.74e-05	0.000223	CcSEcCtD
Tretinoin—Confusional state—Epirubicin—urinary bladder cancer	5.69e-05	0.000221	CcSEcCtD
Tretinoin—Palpitations—Doxorubicin—urinary bladder cancer	5.65e-05	0.00022	CcSEcCtD
Tretinoin—Oedema—Epirubicin—urinary bladder cancer	5.64e-05	0.000219	CcSEcCtD
Tretinoin—Anaphylactic shock—Epirubicin—urinary bladder cancer	5.64e-05	0.000219	CcSEcCtD
Tretinoin—Hypotension—Methotrexate—urinary bladder cancer	5.63e-05	0.000219	CcSEcCtD
Tretinoin—Loss of consciousness—Doxorubicin—urinary bladder cancer	5.62e-05	0.000218	CcSEcCtD
Tretinoin—Infection—Epirubicin—urinary bladder cancer	5.6e-05	0.000218	CcSEcCtD
Tretinoin—Cough—Doxorubicin—urinary bladder cancer	5.58e-05	0.000217	CcSEcCtD
Tretinoin—Shock—Epirubicin—urinary bladder cancer	5.55e-05	0.000216	CcSEcCtD
Tretinoin—Convulsion—Doxorubicin—urinary bladder cancer	5.54e-05	0.000215	CcSEcCtD
Tretinoin—Nervous system disorder—Epirubicin—urinary bladder cancer	5.53e-05	0.000215	CcSEcCtD
Tretinoin—Thrombocytopenia—Epirubicin—urinary bladder cancer	5.52e-05	0.000215	CcSEcCtD
Tretinoin—Hypertension—Doxorubicin—urinary bladder cancer	5.52e-05	0.000215	CcSEcCtD
Tretinoin—Tachycardia—Epirubicin—urinary bladder cancer	5.51e-05	0.000214	CcSEcCtD
Tretinoin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	5.49e-05	0.000213	CcSEcCtD
Tretinoin—Skin disorder—Epirubicin—urinary bladder cancer	5.48e-05	0.000213	CcSEcCtD
Tretinoin—Hyperhidrosis—Epirubicin—urinary bladder cancer	5.45e-05	0.000212	CcSEcCtD
Tretinoin—Insomnia—Methotrexate—urinary bladder cancer	5.45e-05	0.000212	CcSEcCtD
Tretinoin—Arthralgia—Doxorubicin—urinary bladder cancer	5.45e-05	0.000212	CcSEcCtD
Tretinoin—Chest pain—Doxorubicin—urinary bladder cancer	5.45e-05	0.000212	CcSEcCtD
Tretinoin—Myalgia—Doxorubicin—urinary bladder cancer	5.45e-05	0.000212	CcSEcCtD
Tretinoin—Anxiety—Doxorubicin—urinary bladder cancer	5.43e-05	0.000211	CcSEcCtD
Tretinoin—Paraesthesia—Methotrexate—urinary bladder cancer	5.41e-05	0.00021	CcSEcCtD
Tretinoin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	5.41e-05	0.00021	CcSEcCtD
Tretinoin—Discomfort—Doxorubicin—urinary bladder cancer	5.38e-05	0.000209	CcSEcCtD
Tretinoin—Anorexia—Epirubicin—urinary bladder cancer	5.38e-05	0.000209	CcSEcCtD
Tretinoin—Dyspnoea—Methotrexate—urinary bladder cancer	5.37e-05	0.000209	CcSEcCtD
Tretinoin—Somnolence—Methotrexate—urinary bladder cancer	5.36e-05	0.000208	CcSEcCtD
Tretinoin—Dry mouth—Doxorubicin—urinary bladder cancer	5.33e-05	0.000207	CcSEcCtD
Tretinoin—Dyspepsia—Methotrexate—urinary bladder cancer	5.31e-05	0.000206	CcSEcCtD
Tretinoin—Hypotension—Epirubicin—urinary bladder cancer	5.27e-05	0.000205	CcSEcCtD
Tretinoin—Confusional state—Doxorubicin—urinary bladder cancer	5.26e-05	0.000204	CcSEcCtD
Tretinoin—Decreased appetite—Methotrexate—urinary bladder cancer	5.24e-05	0.000204	CcSEcCtD
Tretinoin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	5.22e-05	0.000203	CcSEcCtD
Tretinoin—Oedema—Doxorubicin—urinary bladder cancer	5.22e-05	0.000203	CcSEcCtD
Tretinoin—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	5.2e-05	0.000202	CcSEcCtD
Tretinoin—Fatigue—Methotrexate—urinary bladder cancer	5.2e-05	0.000202	CcSEcCtD
Tretinoin—Infection—Doxorubicin—urinary bladder cancer	5.19e-05	0.000201	CcSEcCtD
Tretinoin—Pain—Methotrexate—urinary bladder cancer	5.16e-05	0.0002	CcSEcCtD
Tretinoin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	5.14e-05	0.0002	CcSEcCtD
Tretinoin—Shock—Doxorubicin—urinary bladder cancer	5.14e-05	0.0002	CcSEcCtD
Tretinoin—Nervous system disorder—Doxorubicin—urinary bladder cancer	5.12e-05	0.000199	CcSEcCtD
Tretinoin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	5.11e-05	0.000199	CcSEcCtD
Tretinoin—Insomnia—Epirubicin—urinary bladder cancer	5.1e-05	0.000198	CcSEcCtD
Tretinoin—Tachycardia—Doxorubicin—urinary bladder cancer	5.09e-05	0.000198	CcSEcCtD
Tretinoin—Skin disorder—Doxorubicin—urinary bladder cancer	5.07e-05	0.000197	CcSEcCtD
Tretinoin—Paraesthesia—Epirubicin—urinary bladder cancer	5.07e-05	0.000197	CcSEcCtD
Tretinoin—Hyperhidrosis—Doxorubicin—urinary bladder cancer	5.05e-05	0.000196	CcSEcCtD
Tretinoin—Dyspnoea—Epirubicin—urinary bladder cancer	5.03e-05	0.000195	CcSEcCtD
Tretinoin—Somnolence—Epirubicin—urinary bladder cancer	5.02e-05	0.000195	CcSEcCtD
Tretinoin—Anorexia—Doxorubicin—urinary bladder cancer	4.98e-05	0.000193	CcSEcCtD
Tretinoin—Feeling abnormal—Methotrexate—urinary bladder cancer	4.97e-05	0.000193	CcSEcCtD
Tretinoin—Dyspepsia—Epirubicin—urinary bladder cancer	4.97e-05	0.000193	CcSEcCtD
Tretinoin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	4.93e-05	0.000191	CcSEcCtD
Tretinoin—Decreased appetite—Epirubicin—urinary bladder cancer	4.9e-05	0.000191	CcSEcCtD
Tretinoin—Hypotension—Doxorubicin—urinary bladder cancer	4.88e-05	0.000189	CcSEcCtD
Tretinoin—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	4.87e-05	0.000189	CcSEcCtD
Tretinoin—Fatigue—Epirubicin—urinary bladder cancer	4.86e-05	0.000189	CcSEcCtD
Tretinoin—Constipation—Epirubicin—urinary bladder cancer	4.82e-05	0.000187	CcSEcCtD
Tretinoin—Pain—Epirubicin—urinary bladder cancer	4.82e-05	0.000187	CcSEcCtD
Tretinoin—Urticaria—Methotrexate—urinary bladder cancer	4.79e-05	0.000186	CcSEcCtD
Tretinoin—Abdominal pain—Methotrexate—urinary bladder cancer	4.77e-05	0.000185	CcSEcCtD
Tretinoin—Body temperature increased—Methotrexate—urinary bladder cancer	4.77e-05	0.000185	CcSEcCtD
Tretinoin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	4.76e-05	0.000185	CcSEcCtD
Tretinoin—Insomnia—Doxorubicin—urinary bladder cancer	4.72e-05	0.000183	CcSEcCtD
Tretinoin—Paraesthesia—Doxorubicin—urinary bladder cancer	4.69e-05	0.000182	CcSEcCtD
Tretinoin—Dyspnoea—Doxorubicin—urinary bladder cancer	4.65e-05	0.000181	CcSEcCtD
Tretinoin—Feeling abnormal—Epirubicin—urinary bladder cancer	4.65e-05	0.000181	CcSEcCtD
Tretinoin—Somnolence—Doxorubicin—urinary bladder cancer	4.64e-05	0.00018	CcSEcCtD
Tretinoin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	4.61e-05	0.000179	CcSEcCtD
Tretinoin—Dyspepsia—Doxorubicin—urinary bladder cancer	4.6e-05	0.000179	CcSEcCtD
Tretinoin—Decreased appetite—Doxorubicin—urinary bladder cancer	4.54e-05	0.000176	CcSEcCtD
Tretinoin—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	4.51e-05	0.000175	CcSEcCtD
Tretinoin—Fatigue—Doxorubicin—urinary bladder cancer	4.5e-05	0.000175	CcSEcCtD
Tretinoin—Urticaria—Epirubicin—urinary bladder cancer	4.48e-05	0.000174	CcSEcCtD
Tretinoin—Pain—Doxorubicin—urinary bladder cancer	4.46e-05	0.000173	CcSEcCtD
Tretinoin—Constipation—Doxorubicin—urinary bladder cancer	4.46e-05	0.000173	CcSEcCtD
Tretinoin—Body temperature increased—Epirubicin—urinary bladder cancer	4.46e-05	0.000173	CcSEcCtD
Tretinoin—Abdominal pain—Epirubicin—urinary bladder cancer	4.46e-05	0.000173	CcSEcCtD
Tretinoin—Hypersensitivity—Methotrexate—urinary bladder cancer	4.44e-05	0.000173	CcSEcCtD
Tretinoin—Asthenia—Methotrexate—urinary bladder cancer	4.33e-05	0.000168	CcSEcCtD
Tretinoin—Feeling abnormal—Doxorubicin—urinary bladder cancer	4.3e-05	0.000167	CcSEcCtD
Tretinoin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	4.27e-05	0.000166	CcSEcCtD
Tretinoin—Pruritus—Methotrexate—urinary bladder cancer	4.27e-05	0.000166	CcSEcCtD
Tretinoin—Hypersensitivity—Epirubicin—urinary bladder cancer	4.16e-05	0.000161	CcSEcCtD
Tretinoin—Urticaria—Doxorubicin—urinary bladder cancer	4.15e-05	0.000161	CcSEcCtD
Tretinoin—Abdominal pain—Doxorubicin—urinary bladder cancer	4.13e-05	0.00016	CcSEcCtD
Tretinoin—Body temperature increased—Doxorubicin—urinary bladder cancer	4.13e-05	0.00016	CcSEcCtD
Tretinoin—Diarrhoea—Methotrexate—urinary bladder cancer	4.12e-05	0.00016	CcSEcCtD
Tretinoin—Asthenia—Epirubicin—urinary bladder cancer	4.05e-05	0.000157	CcSEcCtD
Tretinoin—Pruritus—Epirubicin—urinary bladder cancer	3.99e-05	0.000155	CcSEcCtD
Tretinoin—Dizziness—Methotrexate—urinary bladder cancer	3.99e-05	0.000155	CcSEcCtD
Tretinoin—Diarrhoea—Epirubicin—urinary bladder cancer	3.86e-05	0.00015	CcSEcCtD
Tretinoin—Hypersensitivity—Doxorubicin—urinary bladder cancer	3.85e-05	0.000149	CcSEcCtD
Tretinoin—Vomiting—Methotrexate—urinary bladder cancer	3.83e-05	0.000149	CcSEcCtD
Tretinoin—Rash—Methotrexate—urinary bladder cancer	3.8e-05	0.000148	CcSEcCtD
Tretinoin—Dermatitis—Methotrexate—urinary bladder cancer	3.8e-05	0.000148	CcSEcCtD
Tretinoin—Headache—Methotrexate—urinary bladder cancer	3.78e-05	0.000147	CcSEcCtD
Tretinoin—Asthenia—Doxorubicin—urinary bladder cancer	3.75e-05	0.000145	CcSEcCtD
Tretinoin—Dizziness—Epirubicin—urinary bladder cancer	3.73e-05	0.000145	CcSEcCtD
Tretinoin—Pruritus—Doxorubicin—urinary bladder cancer	3.69e-05	0.000143	CcSEcCtD
Tretinoin—Vomiting—Epirubicin—urinary bladder cancer	3.59e-05	0.000139	CcSEcCtD
Tretinoin—Nausea—Methotrexate—urinary bladder cancer	3.58e-05	0.000139	CcSEcCtD
Tretinoin—Diarrhoea—Doxorubicin—urinary bladder cancer	3.57e-05	0.000139	CcSEcCtD
Tretinoin—Rash—Epirubicin—urinary bladder cancer	3.56e-05	0.000138	CcSEcCtD
Tretinoin—Dermatitis—Epirubicin—urinary bladder cancer	3.55e-05	0.000138	CcSEcCtD
Tretinoin—Headache—Epirubicin—urinary bladder cancer	3.53e-05	0.000137	CcSEcCtD
Tretinoin—Dizziness—Doxorubicin—urinary bladder cancer	3.45e-05	0.000134	CcSEcCtD
Tretinoin—Nausea—Epirubicin—urinary bladder cancer	3.35e-05	0.00013	CcSEcCtD
Tretinoin—Vomiting—Doxorubicin—urinary bladder cancer	3.32e-05	0.000129	CcSEcCtD
Tretinoin—Rash—Doxorubicin—urinary bladder cancer	3.29e-05	0.000128	CcSEcCtD
Tretinoin—Dermatitis—Doxorubicin—urinary bladder cancer	3.29e-05	0.000128	CcSEcCtD
Tretinoin—Headache—Doxorubicin—urinary bladder cancer	3.27e-05	0.000127	CcSEcCtD
Tretinoin—Nausea—Doxorubicin—urinary bladder cancer	3.1e-05	0.00012	CcSEcCtD
Tretinoin—CYP1A1—Metabolism—PRSS3—urinary bladder cancer	1.98e-05	0.000107	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	1.98e-05	0.000107	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.97e-05	0.000106	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	1.95e-05	0.000105	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—NAT1—urinary bladder cancer	1.95e-05	0.000105	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—GSTP1—urinary bladder cancer	1.94e-05	0.000105	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—NAT2—urinary bladder cancer	1.93e-05	0.000104	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.92e-05	0.000104	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.88e-05	0.000101	CbGpPWpGaD
Tretinoin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	1.87e-05	0.000101	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	1.87e-05	0.000101	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—NQO1—urinary bladder cancer	1.85e-05	9.97e-05	CbGpPWpGaD
Tretinoin—RXRA—Gene Expression—NCOR1—urinary bladder cancer	1.82e-05	9.83e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	1.82e-05	9.82e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—RRM2—urinary bladder cancer	1.81e-05	9.79e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—TYMS—urinary bladder cancer	1.81e-05	9.75e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.79e-05	9.68e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	1.79e-05	9.65e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—GSTM1—urinary bladder cancer	1.79e-05	9.64e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—NCOR1—urinary bladder cancer	1.79e-05	9.64e-05	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—MMP9—urinary bladder cancer	1.76e-05	9.51e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—TYMP—urinary bladder cancer	1.72e-05	9.27e-05	CbGpPWpGaD
Tretinoin—RXRA—Gene Expression—ERCC2—urinary bladder cancer	1.71e-05	9.24e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—GPX1—urinary bladder cancer	1.71e-05	9.23e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—GSTP1—urinary bladder cancer	1.7e-05	9.17e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	1.68e-05	9.07e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—ENO2—urinary bladder cancer	1.68e-05	9.07e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—TYMP—urinary bladder cancer	1.68e-05	9.06e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—ERCC2—urinary bladder cancer	1.68e-05	9.06e-05	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—EP300—urinary bladder cancer	1.67e-05	9.01e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—RRM2—urinary bladder cancer	1.66e-05	8.97e-05	CbGpPWpGaD
Tretinoin—RARG—Gene Expression—MYC—urinary bladder cancer	1.66e-05	8.96e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	1.63e-05	8.79e-05	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—SRC—urinary bladder cancer	1.62e-05	8.76e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	1.61e-05	8.69e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.59e-05	8.59e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—TYMP—urinary bladder cancer	1.59e-05	8.56e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—TYMS—urinary bladder cancer	1.58e-05	8.52e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—MTHFR—urinary bladder cancer	1.58e-05	8.52e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.56e-05	8.44e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—NCOR1—urinary bladder cancer	1.56e-05	8.43e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—GSTM1—urinary bladder cancer	1.56e-05	8.43e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—NAT2—urinary bladder cancer	1.55e-05	8.39e-05	CbGpPWpGaD
Tretinoin—RXRA—Generic Transcription Pathway—MYC—urinary bladder cancer	1.55e-05	8.34e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—GSTP1—urinary bladder cancer	1.54e-05	8.32e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—ENO2—urinary bladder cancer	1.54e-05	8.31e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—HPGDS—urinary bladder cancer	1.54e-05	8.31e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.52e-05	8.23e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	1.52e-05	8.2e-05	CbGpPWpGaD
Tretinoin—RXRG—Gene Expression—MYC—urinary bladder cancer	1.52e-05	8.2e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—NAT2—urinary bladder cancer	1.52e-05	8.2e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—GPX1—urinary bladder cancer	1.49e-05	8.07e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—GSTT1—urinary bladder cancer	1.49e-05	8.06e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.49e-05	8.05e-05	CbGpPWpGaD
Tretinoin—RARB—Gene Expression—MYC—urinary bladder cancer	1.49e-05	8.04e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	1.48e-05	7.99e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—ERCC2—urinary bladder cancer	1.47e-05	7.92e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.46e-05	7.87e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—TYMP—urinary bladder cancer	1.45e-05	7.85e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—NAT2—urinary bladder cancer	1.43e-05	7.74e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—TYMS—urinary bladder cancer	1.43e-05	7.73e-05	CbGpPWpGaD
Tretinoin—RXRA—Gene Expression—ESR1—urinary bladder cancer	1.43e-05	7.72e-05	CbGpPWpGaD
Tretinoin—RARA—Gene Expression—MYC—urinary bladder cancer	1.43e-05	7.71e-05	CbGpPWpGaD
Tretinoin—RXRB—Gene Expression—MYC—urinary bladder cancer	1.43e-05	7.71e-05	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—EGFR—urinary bladder cancer	1.42e-05	7.68e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—NCOR1—urinary bladder cancer	1.42e-05	7.64e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—GSTM1—urinary bladder cancer	1.42e-05	7.64e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.4e-05	7.54e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—MTHFR—urinary bladder cancer	1.38e-05	7.45e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.36e-05	7.34e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—GPX1—urinary bladder cancer	1.36e-05	7.32e-05	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—TNF—urinary bladder cancer	1.36e-05	7.32e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—NQO1—urinary bladder cancer	1.35e-05	7.31e-05	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—KRAS—urinary bladder cancer	1.34e-05	7.26e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—RRM2—urinary bladder cancer	1.34e-05	7.24e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—ERCC2—urinary bladder cancer	1.33e-05	7.19e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—NAT2—urinary bladder cancer	1.32e-05	7.1e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—RRM2—urinary bladder cancer	1.31e-05	7.08e-05	CbGpPWpGaD
Tretinoin—RXRA—Gene Expression—PPARG—urinary bladder cancer	1.31e-05	7.05e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.29e-05	6.96e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.29e-05	6.96e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—PPARG—urinary bladder cancer	1.28e-05	6.91e-05	CbGpPWpGaD
Tretinoin—RXRA—Gene Expression—CREBBP—urinary bladder cancer	1.25e-05	6.77e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—MTHFR—urinary bladder cancer	1.25e-05	6.76e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—HPGDS—urinary bladder cancer	1.24e-05	6.7e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—ENO2—urinary bladder cancer	1.24e-05	6.7e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—NQO1—urinary bladder cancer	1.24e-05	6.7e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—RRM2—urinary bladder cancer	1.24e-05	6.69e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—CREBBP—urinary bladder cancer	1.23e-05	6.64e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—ENO2—urinary bladder cancer	1.21e-05	6.55e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	1.21e-05	6.55e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—GSTT1—urinary bladder cancer	1.2e-05	6.5e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.19e-05	6.41e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—TYMP—urinary bladder cancer	1.18e-05	6.39e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.18e-05	6.36e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	1.18e-05	6.36e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—HPGDS—urinary bladder cancer	1.15e-05	6.19e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—ENO2—urinary bladder cancer	1.15e-05	6.19e-05	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—HRAS—urinary bladder cancer	1.14e-05	6.17e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.14e-05	6.16e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.14e-05	6.14e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—RRM2—urinary bladder cancer	1.14e-05	6.13e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	1.13e-05	6.1e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—PPARG—urinary bladder cancer	1.12e-05	6.04e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—GSTT1—urinary bladder cancer	1.11e-05	6.01e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.1e-05	5.91e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—CREBBP—urinary bladder cancer	1.07e-05	5.8e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.07e-05	5.78e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.06e-05	5.73e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—ENO2—urinary bladder cancer	1.05e-05	5.68e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	1.05e-05	5.68e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—TYMS—urinary bladder cancer	1.05e-05	5.67e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.05e-05	5.64e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	1.04e-05	5.6e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	1.04e-05	5.6e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—GSTP1—urinary bladder cancer	1.04e-05	5.59e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	1.02e-05	5.51e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—PPARG—urinary bladder cancer	1.02e-05	5.48e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—PTGS2—urinary bladder cancer	1.01e-05	5.43e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1e-05	5.42e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1e-05	5.41e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—NQO1—urinary bladder cancer	1e-05	5.4e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—GPX1—urinary bladder cancer	9.94e-06	5.36e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—NQO1—urinary bladder cancer	9.79e-06	5.28e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	9.77e-06	5.27e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	9.76e-06	5.27e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—CREBBP—urinary bladder cancer	9.75e-06	5.26e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—TYMS—urinary bladder cancer	9.62e-06	5.19e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—GSTM1—urinary bladder cancer	9.51e-06	5.13e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—NCOR1—urinary bladder cancer	9.51e-06	5.13e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—NQO1—urinary bladder cancer	9.25e-06	4.99e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—RRM2—urinary bladder cancer	9.24e-06	4.99e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	9.17e-06	4.95e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—GPX1—urinary bladder cancer	9.11e-06	4.92e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.97e-06	4.84e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	8.94e-06	4.83e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—PTGS2—urinary bladder cancer	8.8e-06	4.75e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—PTEN—urinary bladder cancer	8.78e-06	4.74e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—ENO2—urinary bladder cancer	8.56e-06	4.62e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	8.56e-06	4.62e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.51e-06	4.59e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—NQO1—urinary bladder cancer	8.48e-06	4.58e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	8.41e-06	4.54e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—EP300—urinary bladder cancer	8.37e-06	4.52e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	8.35e-06	4.51e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	8.3e-06	4.48e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.22e-06	4.44e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.17e-06	4.41e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	8.16e-06	4.41e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—PTGS2—urinary bladder cancer	7.99e-06	4.31e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.82e-06	4.22e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—TYMP—urinary bladder cancer	7.81e-06	4.21e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—TYMS—urinary bladder cancer	7.76e-06	4.19e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	7.71e-06	4.16e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	7.67e-06	4.14e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—PTEN—urinary bladder cancer	7.67e-06	4.14e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	7.67e-06	4.14e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—TYMS—urinary bladder cancer	7.59e-06	4.1e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	7.5e-06	4.05e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	7.5e-06	4.05e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.46e-06	4.03e-05	CbGpPWpGaD
Tretinoin—RXRA—Gene Expression—MYC—urinary bladder cancer	7.44e-06	4.02e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—PPARG—urinary bladder cancer	7.44e-06	4.01e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—GPX1—urinary bladder cancer	7.35e-06	3.97e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—EP300—urinary bladder cancer	7.32e-06	3.95e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	7.22e-06	3.89e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—GPX1—urinary bladder cancer	7.18e-06	3.88e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.17e-06	3.87e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—TYMS—urinary bladder cancer	7.17e-06	3.87e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	7.14e-06	3.86e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	7.09e-06	3.83e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	7.09e-06	3.83e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	7.07e-06	3.82e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—NAT2—urinary bladder cancer	7.06e-06	3.81e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	7.05e-06	3.81e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—PTEN—urinary bladder cancer	6.96e-06	3.76e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—NQO1—urinary bladder cancer	6.9e-06	3.72e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.84e-06	3.69e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—PPARG—urinary bladder cancer	6.82e-06	3.68e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—GPX1—urinary bladder cancer	6.79e-06	3.66e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	6.78e-06	3.66e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.69e-06	3.61e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	6.66e-06	3.6e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—EP300—urinary bladder cancer	6.64e-06	3.58e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	6.63e-06	3.58e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—TYMS—urinary bladder cancer	6.57e-06	3.55e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	6.55e-06	3.53e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	6.5e-06	3.51e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	6.5e-06	3.51e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	6.26e-06	3.38e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—GPX1—urinary bladder cancer	6.22e-06	3.36e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	6.11e-06	3.3e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—RRM2—urinary bladder cancer	6.1e-06	3.29e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	5.85e-06	3.16e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.84e-06	3.15e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	5.75e-06	3.11e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	5.74e-06	3.1e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	5.64e-06	3.05e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—ENO2—urinary bladder cancer	5.64e-06	3.05e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.57e-06	3e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—PPARG—urinary bladder cancer	5.5e-06	2.97e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	5.48e-06	2.96e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—PPARG—urinary bladder cancer	5.38e-06	2.9e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	5.36e-06	2.89e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—TYMS—urinary bladder cancer	5.35e-06	2.89e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	5.29e-06	2.85e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	5.29e-06	2.85e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	5.28e-06	2.85e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	5.16e-06	2.79e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—PTEN—urinary bladder cancer	5.1e-06	2.75e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—PPARG—urinary bladder cancer	5.08e-06	2.74e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—GPX1—urinary bladder cancer	5.06e-06	2.73e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	4.97e-06	2.68e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	4.88e-06	2.63e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—EP300—urinary bladder cancer	4.87e-06	2.63e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—PTEN—urinary bladder cancer	4.68e-06	2.52e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	4.67e-06	2.52e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—PPARG—urinary bladder cancer	4.66e-06	2.51e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—NQO1—urinary bladder cancer	4.55e-06	2.46e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	4.47e-06	2.41e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—EP300—urinary bladder cancer	4.46e-06	2.41e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	4.33e-06	2.34e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	4.23e-06	2.28e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	4e-06	2.16e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.8e-06	2.05e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—PPARG—urinary bladder cancer	3.79e-06	2.05e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—PTEN—urinary bladder cancer	3.77e-06	2.04e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—PTEN—urinary bladder cancer	3.69e-06	1.99e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	3.66e-06	1.98e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	3.64e-06	1.96e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—EP300—urinary bladder cancer	3.6e-06	1.94e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—TYMS—urinary bladder cancer	3.53e-06	1.9e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—EP300—urinary bladder cancer	3.52e-06	1.9e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	3.49e-06	1.88e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	3.49e-06	1.88e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—PTEN—urinary bladder cancer	3.48e-06	1.88e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—GPX1—urinary bladder cancer	3.34e-06	1.8e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—EP300—urinary bladder cancer	3.32e-06	1.79e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	3.28e-06	1.77e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—PTEN—urinary bladder cancer	3.19e-06	1.72e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.08e-06	1.66e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—EP300—urinary bladder cancer	3.05e-06	1.64e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	2.98e-06	1.61e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—PTEN—urinary bladder cancer	2.6e-06	1.4e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.5e-06	1.35e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—EP300—urinary bladder cancer	2.48e-06	1.34e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.4e-06	1.3e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.97e-06	1.06e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.71e-06	9.25e-06	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.64e-06	8.83e-06	CbGpPWpGaD
